Viking Therapeutics Inc (VKTX) News & EventsVKTXViking Therapeutics Inc

Viking Reports Q3 Cash Balance of $960M

At September 30, Viking held cash, cash equivalents, and short-term investments of $960M vs. $706M as of December 31, 2025. "During Q3, Viking continued to advance and expand development activities in its obesity franchise. We recently announced the initiation of the SUNRISE Phase 3 program with the oral tablet formulation of VK2735, representing the third and fourth registration trials to be underway...In Q3 we also announced positive results from our initial VK2735 dose-ranging maintenance study...Also, during the quarter, the Phase 1 study of our dual amylin and calcitonin receptor agonist VK3019 continued to advance. Upon completion, we expect to initiate a 28-day multiple ascending dose study of VK3019 in Q1 of 2027. To support our robust pipeline, as well as the activities related to the potential commercial launch of VK2735, during the quarter the company successfully closed concurrent upsized public offerings of common stock and convertible senior notes, resulting in a strong quarter-end cash balance of $960M . This provides the company with the runway to execute multiple Phase 3 trials and build the infrastructure to execute a strong and effective commercial strategy."

Viking Therapeutics Options Volume Normal, Anticipating 6.6% Move

Pre-earnings options volume in Viking Therapeutics is normal with calls leading puts 5:2. Implied volatility suggests the market is anticipating a move near 6.6%, or $1.65, after results are released. Median move over the past eight quarters is 3.5%.

Investor Sentiment Hit by Bond Market, Oracle Shares Down 9%

Investor sentiment buckled under a one-two punch from fixed income markets on Wednesday.  Hotter than expected CPI inflation data goosed up Treasury yields, with the 10-year spiking to 5.30% and Fed Funds futures pricing in a higher probability of more FOMC tightening.  CME Fed Funds tool estimates October hike at 32% vs. 22% prior and the case for two more consecutive hikes this year at 26% vs. 19% prior.  Then, headlines concerning the corporate bond market spooked investors further as CoreWeave'sunsecured notes due 2032 slid below 80 cents on the dollar, a level broadly viewed as a distress marker, compounding the recent pressure seen in the Tech space.  Oracle, one of the more heavily indebted AI buildout linked names, ended the day down 9% at the lowest level since August.Technology was by far the worst-performing sector in the S&P 500, balanced by the defensively-oriented Consumer Staples and Healthcare.  Tech-heavy Nasdaq Composite ended the day down 2% at the lowest level in nearly a month.  Cautious tone is extending into the evening session - in the opening hours, S&P e-minis are down 0.2% and the Nasdaq 100 contract is down by 0.7%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Rezoluteup 5.9% after completing enrollment in study of ersodetugViking Therapeuticsup 1.4% after being initiated at Buy by UBSDOWN AFTER EARNINGS -Home BancSharesdown 2.5%Equity Bancsharesdown 1.4%ALSO LOWER -Rocket Labdown 6.6% after delaying Neutron launch to 2027 from Q4Spotify Technologydown 1% after downgrade to Hold at StoneXAlbertsons Companiesdown 0.8% after downgrade to Neutral at Goldman Sachs